JPMorgan Reclaims $345 With a Street Still Running to Catch Up

Positioning tells a quiet story that stands in deliberate contrast to the analyst activity. Short interest is effectively trivial for a stock of this size, running at roughly 1% of the free float — 27.2 million shares short as of July 21. That number has drifted up about 4% on the week, but it is down 5% versus a month ago and well off the ~30 million shares that were short through late June and early July. Borrow is extremely loose: availability is at its maximum tracked reading, meaning shares to borrow are in abundant supply. Cost to borrow is 0.32% — cheap even by the standards of large-cap financials — though it has crept up about 20% on the week after touching multi-month lows in late June. None of this points to meaningful short conviction. The options market is marginally more cautious. The put/call ratio of 1.11 is modestly above its 20-day average of 1.08, a difference of less than one standard deviation. That is not a defensive alarm — it is consistent with routine portfolio hedging rather than directional bearishness. The overall lending and derivatives picture reads as relaxed.

Among peers, JPMorgan is not the week's standout mover. Wells Fargo gained 2.9% on the week and U.S. Bancorp added 2.5%, both outpacing JPM's 0.7% weekly gain. Bank of America moved more in line, up 1% on the week. Citigroup was the eye-catcher on the day, rising 3.2% on July 21 — likely reflecting its own earnings-adjacent news. KeyCorp was the notable laggard, falling 1.5% on the week. The modest underperformance by JPMorgan relative to some peers makes sense: the stock already repriced sharply on July 14 and has since consolidated. The catch-up trade, to the extent it exists, is a story for later in the quarter.

On valuation, the trailing P/E has eased to 14.2x — down about 0.3 points over seven days — as the stock consolidated even while forward earnings estimates continued to firm. The price-to-book multiple is 2.41x, down slightly on the week but up modestly over the past month. Neither multiple suggests extreme pricing for a franchise generating the returns JPMorgan has posted. The ORTEX short score of 30.6 is low, consistent with a stock where short sellers have little conviction and the borrow market offers no friction to would-be bears.

Insider activity in the 90-day window has been uniformly in one direction: selling. The General Counsel sold twice, division CEOs and the CFO all filed sales in May, and the COO and Chief Risk Officer trimmed in early May as well. The aggregate is roughly $104 million in net sales. This is standard executive compensation realisation at a large bank rather than a strategic signal — significance scores are low across the board, and the scale of each sale is a fraction of a percent of the company. It is worth noting, not worrying about.

The next quarterly print is not until October 13. Between now and then, the stock's ability to close the gap to consensus targets — currently about $25 wide — will depend on how macro data evolves and whether the loan-loss narrative the bears lean on gains any traction in the economic numbers.